Spots Global Cancer Trial Database for marginal zone lymphoma (mzl)
Every month we try and update this database with for marginal zone lymphoma (mzl) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | NCT05753501 | Hematologic Can... | ABBV-101 | 18 Years - | AbbVie | |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | NCT01282424 | Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | NCT03314922 | Lymphoma | Parsaclisib | 20 Years - | Incyte Corporation | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | NCT05753501 | Hematologic Can... | ABBV-101 | 18 Years - | AbbVie | |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | NCT05131022 | Chronic Lymphoc... Small Lymphocyt... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenstrom Mac... Primary Central... | NX-5948 | 18 Years - | Nurix Therapeutics, Inc. | |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | NCT03314922 | Lymphoma | Parsaclisib | 20 Years - | Incyte Corporation | |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | NCT03547115 | Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Chronic Lymphoc... Diffuse Large B... Acute Myeloid L... | voruciclib mono... voruciclib and ... | 18 Years - | MEI Pharma, Inc. | |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | NCT03314922 | Lymphoma | Parsaclisib | 20 Years - | Incyte Corporation | |
| Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers | NCT04804254 | B-cell Lymphoma | ABBV-623 ABBV-992 | 18 Years - | AbbVie | |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | NCT05720052 | Relapsed or Ref... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Chronic Lymphoc... Small Lymphocyt... Marginal Zone L... | MS-553 | 18 Years - | MingSight Pharmaceuticals, Inc | |
| Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms | NCT06043011 | Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenström's M... | Routine care as... | 18 Years - | iOMEDICO AG | |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | NCT03625037 | DLBCL High-grade B-ce... Primary Mediast... FL MCL Small Lymphocyt... Marginal Zone L... | Epcoritamab | 18 Years - | Genmab | |
| INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | NCT03424122 | B-cell Lymphoma | Parsaclisib Rituximab Bendamustine Ibrutinib | 18 Years - | Incyte Corporation | |
| Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers | NCT04804254 | B-cell Lymphoma | ABBV-623 ABBV-992 | 18 Years - | AbbVie | |
| Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 | NCT03265158 | Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 | NCT03265158 | Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | NCT04830137 | Chronic Lymphoc... Small Lymphocyt... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... Follicular Lymp... Diffuse Large B... Primary Central... | NX-2127 | 18 Years - | Nurix Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
